Similar articles

• A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac arrest.

  Brain Resuscitation Clinical Trial II Study Group. Brain Resuscitation Clinical Trial II Study Group. N Engl J Med. 1991 May 2;324(18):1225-31. doi: 10.1056/NEJM199105023241801. N Engl J Med. 1991. PMID: 2014035 Clinical Trial.
• Lidoflazine in the treatment of comatose survivors of cardiac arrest.

  Engler RL. Engler RL. N Engl J Med. 1991 Oct 3;325(14):1046-7. doi: 10.1056/nejm199110033251416. N Engl J Med. 1991. PMID: 1886630 No abstract available.
• A randomized clinical trial of calcium entry blocker administration to comatose survivors of cardiac arrest. Design, methods, and patient characteristics. The Brain Resuscitation Clinical Trial II Study Group.

  [No authors listed] [No authors listed] Control Clin Trials. 1991 Aug;12(4):525-45. doi: 10.1016/0197-2456(91)90011-a. Control Clin Trials. 1991. PMID: 1657528 Clinical Trial.
• Neurologic outcomes after cardiac resuscitation.

  Shively M, Norton L, Mendez K. Shively M, et al. J Cardiovasc Nurs. 1996 Jul;10(4):93-6. doi: 10.1097/00005082-199607000-00010. J Cardiovasc Nurs. 1996. PMID: 8796493 Review.
• [Cerebral protection following cardiopulmonary arrest: reality, pipe dream or utopia?].

  Calle PA, Bogaert MG, Buylaert WA. Calle PA, et al. Ned Tijdschr Geneeskd. 1992 Oct 24;136(43):2114-7. Ned Tijdschr Geneeskd. 1992. PMID: 1436172 Review. Dutch. No abstract available.